-
Mashup Score: 0Immunotherapy-TKI Combo More Effective for Intermediate-Risk RCC - Renal and Urology News - 9 hour(s) ago
Investigators question the usefulness of TKI-IO combinations in poor-risk disease.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Adjuvant Pembrolizumab Prolongs Overall Survival in Clear Cell RCC - Renal and Urology News - 7 day(s) ago
One in 5 patients treated with adjuvant pembrolizumab experienced serious adverse events, so it remains important to weigh the risk vs benefits of the therapy for each individual patient.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC - 17 day(s) ago
NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC - 19 day(s) ago
NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
For intermediate-risk renal cell carcinoma, better survival outcomes occur when an immunotherapy is combined with a tyrosine kinase inhibitor (IO+TKI) rather than another immunotherapy therapy (IO+IO), according to a real-world study. https://t.co/UR96YurEsK #kcsm